FDA 483 - Paul Schulz, M.D. - July 22, 2025

Paul Schulz, M.D., a clinical investigator in Houston, TX, was inspected by the FDA and received a Form 483 with three observations. The inspection revealed significant deficiencies in obtaining informed consent, maintaining accurate case histories, and ensuring proper study monitoring. These issues indicate a lack of adherence to regulatory requirements for clinical investigations.